Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Cabozantinib + unspecified CTLA4 antibody + unspecified PD-1 antibody |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Cabozantinib | Cometriq | Cabometyx|Cabozantinib-s-malate|XL184 | AXL Inhibitor 27 FLT3 Inhibitor 55 KIT Inhibitor 51 MET Inhibitor 51 RET Inhibitor 39 ROS1 Inhibitor 14 VEGFR2 Inhibitor 35 | Cometriq (Cabometyx, cabozantinib) inhibits several receptor tyrosine kinases, including VEGFR2, FLT3, AXL, MET, RET, ROS1 fusions, and c-KIT (PMID: 27370605, PMID: 21926191). Cometriq (cabozantinib) is FDA approved for use in patients with medullary thyroid cancer, Cabometyx (cabozantinib) is FDA approved for use in patients with advanced renal cell carcinoma, hepatocellular carcinoma previously treated with sorafenib, and in combination with Opdivo (nivolumab) in patients with advanced renal cell carcinoma (FDA.gov). |
unspecified CTLA4 antibody | experimental CTLA4 antibody | |||
unspecified PD-1 antibody | Experimental PD-1 antibody | PD-L1/PD-1 antibody 68 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
Unknown unknown | prostate cancer | not applicable | Cabozantinib + unspecified CTLA4 antibody + unspecified PD-1 antibody | Preclinical | Actionable | In a preclinical study, combination of myeloid-derived suppressor cell-targeting with Cometriq (cabozantinib) and immune checkpoint blockade with anti-CTLA4 and anti-PD-1 antibodies resulted in synergistic inhibition of tumor growth and metastasis in transgenic mouse models of metastatic castration-resistant prostate cancer (PMID: 28321130). | 28321130 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|